Predica Diagnostics

Predica Diagnostics is a medical‑diagnostics startup (a spin‑off from RadboudUMC) that develops and markets assays for oncology and women’s health using their proprietary targeted RNA‑sequencing technology (ciRNAseq).

Their first product, CervicaDx, aims to improve cervical cancer screening by providing non‑invasive, high‑specificity detection of cervical abnormalities, reducing overdiagnosis and overtreatment compared to current HPV‑based tests. Their mission is to ensure patients only undergo medically necessary procedures — by offering more precise diagnostics and treatment guidance. 

Our news

March 6, 2026

819 Capital Partners acquires key assets of Lead Pharma, enabling continuation of operations

Deventer, 6 March 2026 - 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs. The transaction includes intellectual property rights, research data, and selected development programs. Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies...

Continue reading
February 10, 2026

819 Capital Partners acquires Chalet.nl

Deventer, 10 February 2026 – 819 Capital Partners announces the acquisition of Chalet.nl, a well-established Dutch touroperator that has been a leading authority in winter sports holidays for more than 25 years. Chalet.nl specializes in the organization and rental of chalets and apartments in leading winter sports destinations across France, Austria, Switzerland and Italy. The company has built a strong online presence and is known for its reliable service, personal approach, and deep expertise in...

Continue reading